Beck Mack & Oliver’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-13,235
| Closed | -$836K | – | 200 |
|
|
2020
Q3 | $836K | Sell |
13,235
-5,300
| -29% | -$368K | 0.03% | 113 |
|
|
2020
Q2 | $1.43M | Sell |
18,535
-31,791
| -63% | -$2.44M | 0.05% | 91 |
|
|
2020
Q1 | $3.76M | Sell |
50,326
-240,385
| -83% | -$16.6M | 0.17% | 62 |
|
|
2019
Q4 | $18.9M | Sell |
290,711
-53,507
| -16% | -$3.48M | 0.62% | 41 |
|
|
2019
Q3 | $21.8M | Sell |
344,218
-20,772
| -6% | -$1.36M | 0.77% | 35 |
|
|
2019
Q2 | $24.7M | Sell |
364,990
-4,521
| -1% | -$297K | 0.87% | 33 |
|
|
2019
Q1 | $24M | Sell |
369,511
-2,339
| -0.6% | -$155K | 0.86% | 35 |
|
|
2018
Q4 | $23.3M | Sell |
371,850
-30,642
| -8% | -$2.14M | 0.93% | 33 |
|
|
2018
Q3 | $31.1M | Buy |
402,492
+6,876
| +2% | +$519K | 0.99% | 32 |
|
|
2018
Q2 | $28M | Buy |
395,616
+12,125
| +3% | +$856K | 0.94% | 35 |
|
|
2018
Q1 | $28.9M | Buy |
383,491
+20,703
| +6% | +$1.65M | 0.97% | 35 |
|
|
2017
Q4 | $26M | Sell |
362,788
-18,765
| -5% | -$1.43M | 0.85% | 38 |
|
|
2017
Q3 | $30.9M | Sell |
381,553
-12,038
| -3% | -$921K | 1.02% | 36 |
|
|
2017
Q2 | $27.9M | Sell |
393,591
-1,461
| -0.4% | -$97.2K | 0.94% | 36 |
|
|
2017
Q1 | $26.8M | Sell |
395,052
-264,370
| -40% | -$18.6M | 0.94% | 37 |
|
|
2016
Q4 | $47.2M | Buy |
659,422
+9,383
| +1% | +$697K | 1.7% | 23 |
|
|
2016
Q3 | $51.4M | Buy |
650,039
+144,694
| +29% | +$11.8M | 1.85% | 21 |
|
|
2016
Q2 | $42.2M | Buy |
505,345
+243,770
| +93% | +$21.6M | 1.49% | 27 |
|
|
2016
Q1 | $24M | Buy |
261,575
+257,943
| +7,102% | +$23.3M | 0.84% | 39 |
|
|
2015
Q4 | $368K | Sell |
3,632
-256
| -7% | -$26.6K | 0.01% | 212 |
|
|
2015
Q3 | $382K | Hold |
3,888
| – | – | 0.01% | 233 |
|
|
2015
Q2 | $455K | Sell |
3,888
-54
| -1% | -$5.9K | 0.01% | 236 |
|
|
2015
Q1 | $387K | Buy |
3,942
+98
| +3% | +$9.95K | 0.01% | 253 |
|
|
2014
Q4 | $362K | Buy |
3,844
+74
| +2% | +$7.65K | 0.01% | 262 |
|
|
2014
Q3 | $401K | Sell |
3,770
-1,035
| -22% | -$101K | 0.01% | 257 |
|
|
2014
Q2 | $399K | Buy |
4,805
+155
| +3% | +$12.1K | 0.01% | 261 |
|
|
2014
Q1 | $329K | Hold |
4,650
| – | – | 0.01% | 269 |
|
|
2013
Q4 | $349K | Hold |
4,650
| – | – | 0.01% | 269 |
|
|
2013
Q3 | $292K | Hold |
4,650
| – | – | 0.01% | 280 |
|
|
2013
Q2 | $239K | Buy |
+4,650
| New | +$242K | 0.01% | 310 |
|
Other funds holding GILD
Beck Mack & Oliver's GILD Position: Q4 2020 in Review
Beck Mack & Oliver sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 13,235 shares — an estimated $836K sold.
Beck Mack & Oliver first reported a position in GILD in Q2 2013 and held it in 30 quarters. The position peaked at $51.4M in Q3 2016. 1,564 funds tracked by Wall St. Rank hold GILD as of Q4 2020.
- Beck Mack & Oliver reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
- Beck Mack & Oliver sold 13,235 Gilead Sciences shares in Q4 2020, an estimated $836K.
- Beck Mack & Oliver first reported a position in Gilead Sciences in Q2 2013 and held it in 30 quarters.
- Beck Mack & Oliver's Gilead Sciences position peaked at $51.4M in Q3 2016.
- 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.
Based on Beck Mack & Oliver's 13F filing for Q4 2020, filed 10 Feb 2021.